A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.

doi:10.1016/j.ahj.2017.12.001

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.

American heart journal - 1 May 2018

Piccini Jonathan P, Connolly Stuart J, Abraham William T, Healey Jeff S, Steinberg Benjamin A, Al-Khalidi Hussein R, Dignacco Patricia, van Veldhuisen Dirk J, Sauer William H, White Michel, Wilton Stephen B, Anand Inder S, Dufton Christopher, Marshall Debra A, Aleong Ryan G, Davis Gordon W, Clark Richard L, Emery Laura L, Bristow Michael R

Abstract excerpt

BACKGROUND: Few therapies are available for the safe and effective treatment of atrial fibrillation (AF) in patients with heart failure. Bucindolol is a non-selective beta-blocker with mild vasodilator activity previously found to have accentuated antiarrhythmic effects and increased efficacy for preventing heart failure events in patients homozygous for the major allele of the ADRB1 Arg389Gly polymorphism (ADRB1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Arrhythmia Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Atrial Fibrillation

Share to Double-Blind Method

Share to Heart Failure

Share to Metoprolol

Share to Propanolamines

Share to Receptors, Adrenergic, beta-1

Share to Stroke Volume

Source

Open in PubMed

Identifiers

PMID: 29754666
DOI: 10.1016/j.ahj.2017.12.001

Genes

ADRB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.PMID 29754666Read ↗

Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure.Semantic proximity Read ↗

Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation.Semantic proximity Read ↗

Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype.Semantic proximity Read ↗

A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.Semantic proximity Read ↗

Combinatorial Pharmacogenetic Interactions of Bucindolol and β1, α2C Adrenergic Receptor PolymorphismsSemantic proximity Read ↗

G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT.Semantic proximity Read ↗

NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial.Semantic proximity Read ↗

Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients.Semantic proximity Read ↗

β<sub>1</sub>- and β<sub>2</sub>-adrenergic Receptor Haplotypes Regulate Therapeutic Responses to Placebo and the Biased Ligand β-blocker BucindololSemantic proximity Read ↗

Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure.Semantic proximity Read ↗

Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.Semantic proximity Read ↗

Racial differences in heart failure therapeutics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.